沈阳红旗制药：自主研发环丝氨酸胶囊获国家药品监督管理局上市批准

和讯网04-24

快讯正文【复星医药成功研发新药获国家药品监督管理局批准上市】复星医药公告，其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准，用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核（包括肾结核）的治疗。环丝氨酸胶囊的上市注册申请属于自主研发，标志着复星医药在抗结核药物领域的技术实力。复星医药表示，环丝氨酸胶囊的上市将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2430478626?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-24 17:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2430478626","market":"hk","top_or_hot":-1,"title":"沈阳红旗制药：自主研发环丝氨酸胶囊获国家药品监督管理局上市批准","media":"和讯网","content":"<div>\n<p>快讯正文【复星医药成功研发新药 获国家药品监督管理局批准上市】复星医药公告，其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准，用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核（包括肾结核）的治疗。环丝氨酸胶囊的上市注册申请属于自主研发，标志着复星医药在抗结核药物领域的技术实力。复星医药表示，环丝氨酸胶囊的上市将...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>沈阳红旗制药：自主研发环丝氨酸胶囊获国家药品监督管理局上市批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n沈阳红旗制药：自主研发环丝氨酸胶囊获国家药品监督管理局上市批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 17:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯正文【复星医药成功研发新药 获国家药品监督管理局批准上市】复星医药公告，其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准，用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核（包括肾结核）的治疗。环丝氨酸胶囊的上市注册申请属于自主研发，标志着复星医药在抗结核药物领域的技术实力。复星医药表示，环丝氨酸胶囊的上市将...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b","article_id":"2430478626","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042417385487aa4213&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2430478626","pubTimestamp":1713950565,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯正文【复星医药成功研发新药 获国家药品监督管理局批准上市】复星医药公告，其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准，用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核（包括肾结核）的治疗。环丝氨酸胶囊的上市注册申请属于自主研发，标志着复星医药在抗结核药物领域的技术实力。复星医药表示，环丝氨酸胶囊的上市将增强其在抗结核药物市场的竞争力，为公司业绩增长带来新的增长点。公司将致力于提升产品质量，优化生产工艺，不断满足市场需求，助力中国抗结核药物研发事业的发展。下载和讯APP查看快讯，体验更佳>>","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","02196":"复星医药","BK1574":"生物医药B类股","BK1191":"制药","BK1515":"抗疫概念","01477":"欧康维视生物-B"},"translate_title":"Shenyang Hongqi Pharmaceutical: Self-developed cycloserine capsules were approved by the State Drug Administration for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"01477":1,"02196":0.9},"content_text":"快讯正文【复星医药成功研发新药 获国家药品监督管理局批准上市】复星医药公告，其控股子公司沈阳红旗制药有限公司自主创新研发的环丝氨酸胶囊已经获得国家药品监督管理局的官方批准，用于治疗对一线抗结核药物不敏感的结核病患者。该胶囊适用于结核菌引起的活动性肺结核及肺外结核（包括肾结核）的治疗。环丝氨酸胶囊的上市注册申请属于自主研发，标志着复星医药在抗结核药物领域的技术实力。复星医药表示，环丝氨酸胶囊的上市将增强其在抗结核药物市场的竞争力，为公司业绩增长带来新的增长点。公司将致力于提升产品质量，优化生产工艺，不断满足市场需求，助力中国抗结核药物研发事业的发展。下载和讯APP查看快讯，体验更佳>>","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430478626"}